Navigation Links
Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
Date:10/30/2013

CAMBRIDGE, England, October 30, 2013 /PRNewswire/ --

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications.

CINV occurs in approximately 70% of all cancer patients receiving chemotherapy and in 90% of those receiving highly emetogenic chemotherapy (HEC). It is one of the major side effects of cancer therapy and a considerable concern for patients. There are two major types of CINV, referred to as acute CINV which occurs on the day of treatment, and delayed CINV which occurs up to five days following chemotherapy. Despite the improvements in managing CINV there remains a clear unmet need to reduce the incidence of nausea, especially in delayed CINV, as standard regimens are relatively effective at stopping patients being sick (vomiting) but much less so at stopping them feeling sick (nausea), which is often the most distressing symptom.

The Phase II study is taking place in around 25 major centres in the UK, Denmark, Germany and the USA and aims to recruit 315 cancer patients receiving HEC. The trial compares 3 doses of APD403 against placebo in the delayed phase of CINV. The primary endpoint is no vomiting or retching and no requirement for anti-emetic rescue medication for 5 days after the start of chemotherapy administration. The incidence and severity of nausea is being studied as a secondary endpoint.

Acacia Pharma has previously generated positive Phase IIa clinical data when the drug was given prophylactically to cancer patients being treated with the HEC, cisplatin. These data showed APD403 has t
'/>"/>

SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
2. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Both Shape and Volumetric Evaluation of ... Three dimensional visualization,of the right ventricle provides important ... patients with tetralogy of,Fallot (TOF), according to a paper ... 1, 107-113)., TOF is a disease that impacts ...
... April 8, 2008 ,Anesiva, Inc. (Nasdaq: ANSV ... trial evaluating Adlea(TM), its long-acting, non-opioid analgesic,drug candidate, ... In September 2007, Anesiva initiated a multicenter, ... safety and,efficacy of a single 5 or 15 ...
Cached Medicine Technology:Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 2Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 3Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement 4
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... Glan Clywd Hospital will soon offer local cancer patients ... radiotherapy technology on two new treatment machines from Varian ... the Clinac(R) linear accelerators with RapidArc are installed, the ... to offer this new, faster form of radiotherapy that ...
... (NYSE: DHR ) announced today that ... quarterly dividend of $0.03 per share payable on ... June 26, 2009.Danaher Corporation is a leading manufacturer ... Tools and Components ( www.danaher.com ). ...
... Outpatient, Inpatient SettingsBOSTON, May 7 MedAptus(R), market ... the distinguished Lenox Hill Interventional Cardiac & Vascular ... to implement Professional Intelligent Charge Capture. Nearly ... of the most highly respected cardiovascular care programs ...
... Ohio, May 7 STERIS Corporation (NYSE: STE ... a 38% increase in its quarterly dividend to $0.11 per ... to shareholders of record at the close of business on ... of STERIS Corporation is to provide a healthier today and ...
... EPS Guidance , WARSAW, Ind., May 7 First Quarter 2009 Highlights: ... Revenue of $101.4 million, comparable year-over-year and up 6.8% on a constant currency ... 24.2%, up 70 basis points year-over-year and up 80 basis points over the ... Operating income of $11.2 million, up 17.2% year-over-year and up 18.2% over the ...
... a.m. EDT at www.isispharm.com CARLSBAD, Calif., May 7 ... announced its financial results for the quarter ended March 31, ... gain that Isis recognized from selling its Ibis Biosciences subsidiary ... of 2009 with pro forma net income of $173.0 million. ...
Cached Medicine News:Health News:Cancer Patients in North Wales to Gain Access to Varian's RapidArc Radiotherapy Treatments 2Health News:MedAptus' Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice 2Health News:MedAptus' Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice 3Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 2Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 3Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 4Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 5Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 6Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 7Health News:Symmetry Medical Reports First Quarter 2009 Financial Results 8Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 2Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 3Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 4Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 5Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 6Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 7Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 8Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 9Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 10Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 11Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 12Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 13Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 14Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 15Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 16Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 17Health News:Isis Reports Strong Financial Results and Highlights for First Quarter of 2009 18
... Four 62 mirrors ... the angle with little ... flange is convenient for ... fissures. Anterior holding ring ...
Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
Mcintyre straight lachrymal cannula, closed end, two side ports at 0.3 mm, straight shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: